# Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

> **NCT00005052** · PHASE3 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** GM2-KLH vaccine
- **BIOLOGICAL:** QS21
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00005052
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005052, "Vaccine Therapy in Treating Patients With Primary Stage II Melanoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00005052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*